Low molecular weight hyaluronan-pulsed human dendritic cells showed increased migration capacity and induced resistance to tumor chemoattraction

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Rizzo, Manglio ^a   Bayo, Juan ^a   Piccioni, Flavia ^a   Malvicini, Mariana ^a,b   Fiore, Esteban ^a   Peixoto, Estanislao ^a   García, Mariana G ^a,b   Aquino, Jorge B ^a,b   Campaña, Ariel Gonzalez ^a   Podestá, Gustavo ^a   Terres, Marcelo ^a   Andriani, Oscar ^a   Alaniz, Laura ^b,c   Mazzolini, Guillermo ^a,b  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b CABA ^*  (Argentina)

^c Universidad Nacional del Noroeste de la Provincia de Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; HYALURONIC ACID; INTERLEUKIN 8; METALLOPROTEINASE; SECONDARY LYMPHOID TISSUE CHEMOKINE; CULTURE MEDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CELL MIGRATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; IN VITRO STUDY; LEUKOCYTE; LYMPHOCYTE PROLIFERATION; MONOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; CELL MOTION; COLORECTAL TUMOR; CULTURE MEDIUM; DRUG EFFECTS; IMMUNOLOGY; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

CELL MOVEMENT; COLORECTAL NEOPLASMS; CULTURE MEDIA; DENDRITIC CELLS; HUMANS; HYALURONIC ACID; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84907200351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107944     Document Type: Article

References (65)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, et al. (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113: 1515-1525.
3. Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4: 401-411.
4. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
5. Segura E, Albiston AL, Wicks IP, Chai SY, Villadangos JA (2009) Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc Natl Acad Sci U S A 106: 20377-20381.
6. Alvarez D, Vollmann EH, von Andrian UH (2008) Mechanisms and consequences of dendritic cell migration. Immunity 29: 325-342.
7. Silk KM, Silk JD, Ichiryu N, Davies TJ, Nolan KF, et al. (2011) Crosspresentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1(+) dendritic cells. Gene Ther.
8. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, et al. (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59: 56-58.
9. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, et al. (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63: 12-17.
10. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, et al. (2003) Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198: 615-621.
11. Alaniz L, Rizzo M, Garcia MG, Piccioni F, Aquino JB, et al. (2011) Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma. Cancer Immunol Immunother 60: 1383-1395.
12. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, et al. (1998) Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188: 373-386.
13. Ahamed J, Haribabu B, Ali H (2001) Cutting edge: Differential regulation of chemoattractant receptor-induced degranulation and chemokine production by receptor phosphorylation. J Immunol 167: 3559-3563.
14. Allavena P, Sica A, Vecchi A, Locati M, Sozzani S, et al. (2000) The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev 177: 141-149.
15. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M (2002) Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocytederived dendritic cells. Blood 100: 1354-1361.
16. Moller I, Michel K, Frech N, Burger M, Pfeifer D, et al. (2008) Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application. J Immunother 31: 506-519.
17. Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7: 454-465.
18. Bartz H, Avalos NM, Baetz A, Heeg K, Dalpke AH (2006) Involvement of suppressors of cytokine signaling in toll-like receptor-mediated block of dendritic cell differentiation. Blood 108: 4102-4108.
19. Hurwitz AA, Watkins SK (2012) Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother 61: 289-293.
20. Xie K (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391.
21. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, et al. (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70: 1063-1071.
22. Feijoo E, Alfaro C, Mazzolini G, Serra P, Penuelas I, et al. (2005) Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 116: 275-281.
23. Alfaro C, Suarez N, Martinez-Forero I, Palazon A, Rouzaut A, et al. (2011) Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS One 6: e17922.
24. Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539.
25. McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, et al. (1996) Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 98: 2403-2413.
26. McKee CM, Lowenstein CJ, Horton MR, Wu J, Bao C, et al. (1997) Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor kappaB-dependent mechanism. J Biol Chem 272: 8013-8018.
27. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, et al. (2002) Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195: 99-111.
28. Termeer CC, Hennies J, Voith U, Ahrens T, Weiss JM, et al. (2000) Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol 165: 1863-1870.
29. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, et al. (2006) Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 177: 1272-1281.
30. Rodriguez-Salvador J, Armas-Pineda C, Perezpena-Diazconti M, Chico-Ponce de Leon F, Sosa-Sainz G, et al. (2005) Effect of sodium butyrate on pro-matrix metalloproteinase-9 and-2 differential secretion in pediatric tumors and cell lines. J Exp Clin Cancer Res 24: 463-473.
31. Adema GJ, de Vries IJ, Punt CJ, Figdor CG (2005) Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 17: 170-174.
32. Verdijk P, Aarntzen EH, Punt CJ, de Vries IJ, Figdor CG (2008) Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther 8: 865-874.
33. Sozzani S, Allavena P, Vecchi A, Mantovani A (2000) Chemokines and dendritic cell traffic. J Clin Immunol 20: 151-160.
34. Bianchi G, D'Amico G, Varone L, Sozzani S, Mantovani A, et al. (2000) In vitro studies on the trafficking of dendritic cells through endothelial cells and extracellular matrix. Dev Immunol 7: 143-153.
35. Ratzinger G, Stoitzner P, Ebner S, Lutz MB, Layton GT, et al. (2002) Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 168: 4361-4371.
36. Lesley J, Hascall VC, Tammi M, Hyman R (2000) Hyaluronan binding by cell surface CD44. J Biol Chem 275: 26967-26975.
37. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, et al. (2004) Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 279: 17079-17084.
38. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G (2003) Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 46: 33-57.
39. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449: 419-426.
40. Dauer M, Schnurr M, Eigler A (2008) Dendritic cell-based cancer vaccination: quo vadis? Expert Rev Vaccines 7: 1041-1053.
41. Pascual V, Allantaz F, Patel P, Palucka AK, Chaussabel D, et al. (2008) How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev 223: 39-59.
42. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
43. Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, et al. (2009) Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 58: 1329-1336.
44. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G (2001) Dendritic cells as vectors for therapy. Cell 106: 271-274.
45. Do Y, Nagarkatti PS, Nagarkatti M (2004) Role of CD44 and hyaluronic acid (HA) in activation of alloreactive and antigen-specific T cells by bone marrowderived dendritic cells. J Immunother 27: 1-12.
46. Mummert ME (2005) Immunologic roles of hyaluronan. Immunol Res 31: 189-206.
47. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, et al. (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88: 1747-1754.
48. Lang S, Lauffer L, Clausen C, Lohr I, Schmitt B, et al. (2003) Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB J 17: 286-288.
49. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, et al. (2001) Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 166: 249-255.
50. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, et al. (2011) Route of administration modulates the induction of dendritic cell vaccineinduced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17: 5725-5735.
51. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, et al. (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23: 1407-1413.
52. van Helden SF, Krooshoop DJ, Broers KC, Raymakers RA, Figdor CG, et al. (2006) A critical role for prostaglandin E2 in podosome dissolution and induction of high-speed migration during dendritic cell maturation. J Immunol 177: 1567-1574.
53. Parks WC, Wilson CL, Lopez-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4: 617-629.
54. Noble PW, McKee CM, Cowman M, Shin HS (1996) Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 183: 2373-2378.
55. Fieber C, Baumann P, Vallon R, Termeer C, Simon JC, et al. (2004) Hyaluronan-oligosaccharide-induced transcription of metalloproteases. J Cell Sci 117: 359-367.
56. Kim Y, Lee YS, Choe J, Lee H, Kim YM, et al. (2008) CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 283: 22513-22528.
57. Alaniz L, Garcia M, Rizzo M, Piccioni F, Mazzolini G (2009) Altered hyaluronan biosynthesis and cancer progression: an immunological perspective. Mini Rev Med Chem 9: 1538-1546.
58. Yamawaki H, Hirohata S, Miyoshi T, Takahashi K, Ogawa H, et al. (2009) Hyaluronan receptors involved in cytokine induction in monocytes. Glycobiology 19: 83-92.
59. Isacke CM, Yarwood H (2002) The hyaluronan receptor, CD44. Int J Biochem Cell Biol 34: 718-721.
60. Miaw SC, Chen JS, Hsieh PC, Liu CY, Chung MH, et al. (2010) CD44-deficient mice do not exhibit impairment of epidermal Langerhans cell migration to lymph nodes after epicutaneous sensitization with protein. J Invest Dermatol 130: 2674-2677.
61. Mascarenhas MM, Day RM, Ochoa CD, Choi WI, Yu L, et al. (2004) Low molecular weight hyaluronan from stretched lung enhances interleukin-8 expression. Am J Respir Cell Mol Biol 30: 51-60.
62. Voelcker V, Gebhardt C, Averbeck M, Saalbach A, Wolf V, et al. (2008) Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 17: 100-107.
63. Kim H, Koh G (2000) Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun 269: 401-405.
64. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, et al. (1997) Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 151: 1105-1113.
65. Gebhardt C, Averbeck M, Viertel A, Kauer F, Saalbach A, et al. (2007) Ultraviolet-B irradiation enhances melanoma cell motility via induction of autocrine interleukin 8 secretion. Exp Dermatol 16: 636-643.